Chemo-radiation with two drugs for limited-stage small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests combining standard chemotherapy with radiation (chemoradiotherapy) plus two additional drugs, toripalimab and surufatinib, for people with limited-stage small cell lung cancer. The goal is to see if this combination improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old.
- You must have small cell lung cancer that has not spread beyond one side of the chest (limited-stage).
- You must be in fairly good health with a performance status of 0 or 1 (able to carry on daily activities).
- You need adequate lung, kidney, and liver function (specific blood and breathing test results).
- If you are of childbearing age, you must agree to use effective contraception during and for a period after treatment.
- You must not have had prior treatment with a PD-1 or PD-L1 inhibitor (a type of immunotherapy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy, radiation, and two targeted drugs (surufatinib and tislelizumab) for people with stage III non-small cell lung cancer that cannot be surgically removed. The goal is to see if this approach works better than standard treatment.
This trial tests whether adding toripalimab (an immunotherapy) or toripalimab plus another immunotherapy (tifcemalimab) after standard chemoradiation can help prevent small cell lung cancer from coming back. It is for people with limited-stage disease who have finished initial treatment without the cancer growing.
This trial tests a treatment plan that combines a short course of radiation with chemotherapy and an immunotherapy drug (adebrelimab). It is for people with limited-stage small cell lung cancer who haven't had treatment yet.
This trial tests whether taking tislelizumab plus nintedanib after initial radiation and chemotherapy can help keep limited-stage small cell lung cancer from coming back. It is for people who have finished induction treatment and are in good overall health.
This trial tests an investigational drug called QL1706 combined with chemotherapy, given after standard chemoradiation, for people with limited-stage small cell lung cancer. The goal is to see if this combination helps keep the cancer from coming back.
This trial tests whether adding two drugs (adebrelimab and apatinib) after standard chemoradiation can help prevent cancer from coming back in people with limited-stage small cell lung cancer. It is for patients whose cancer did not grow after chemoradiation.
Hear when a new Toripalimab trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.